Author(s) :

Aisha Mukhamejanova.

Volume/Issue :

Abstract :

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia worldwide. It is characterized by the accumulation of amyloid plaques and neurofibrillary tangles, often linked to pathogenic gene mutations. As no curative treatment is currently available, researchers are increasingly exploring CRISPR-based strategies, such as base editing, prime editing, and epigenetic editing, as potential therapeutic options. This review examines studies published since 2020 on the application of CRISPR technologies in the context of AD. The evidence highlights the considerable potential of gene editing for targeting AD-associated genes and alleviating disease-related pathology. However, all reported findings remain at the preclinical stage, as key barriers, particularly low editing efficiency and delivery challenges, in delivering CRISPR components to the brain.